SAN DIEGO, May 11, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it presented data at the American Society of Gene and Cell Therapy 20th Annual Meeting (ASGCT).
Details of the presentations are as follows. The presentation slides and poster can be accessed by visiting the publications and presentations section of the Company's website at www.tocagen.com.
Title: Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial
Presentation Type: Podium
Session: Immunotherapy Clinical Trials for Cancer
Presenter: Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen
Summary: As previously presented, data from three Phase 1 trials of Toca 511 and Toca FC in 126 patients with recurrent high grade glioma demonstrate potential benefits, including durable objective responses, extended overall survival and a favorable safety profile.
Title: TOCA 511 & 5-FC: Anti-tumor activity, immune memory and prolonged survival even at low infection levels
Presentation Type: Poster
Session: Cancer-Immunotherapy, Cancer Vaccines I
Presenter: Kader Yagiz, Ph.D., research scientist at Tocagen
Summary: Data from preclinical models suggest that even a small percentage of Toca 511 infection results in anti-tumor immune activation and a significant increase in survival following 5-FC treatment.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Toca 511 & Toca FC was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tocagen-presents-data-at-the-american-society-of-gene-and-cell-therapy-20th-annual-meeting-300455756.html
SOURCE Tocagen Inc.
Media Contact: Monica May, Canale Communications, (619) 849-5383, firstname.lastname@example.org; Investor Contact: Elizabeth Broder, The Trout Group, (646) 378-2945, email@example.com